Panther Fusion® MRSA Assay

Fully Automated. Efficiency. Performance.

The Panther Fusion MRSA assay is designed for the qualitative detection and differentiation of Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs in patients at risk for nasal colonization. It is intended to aid in the prevention and control of SA and MRSA infections in healthcare settings.

The Panther Fusion MRSA assay allows for direct loading of ESwab nasal samples on the Panther Fusion® system. It has broad strain inclusivity, including the Bengal Bay clone. It also correctly identifies empty cassette variants.1

Elevate Your Laboratory

There are several key takeaways for laboratory success with the Panther Fusion MRSA assay. The Panther Fusion MRSA assay has advantages when compared with culture, laboratory-developed tests and other IVDs.2

Labor and Time Savings

Load samples and walkaway to free up staff for other activities. Streamline the pathway for MRSA testing and eliminate the need to enrich samples for molecular testing. Random access capabilities enhance infection control efforts, saving time with batch-free processing.

Performance Benefits

Provide clinicians with fast and accurate results, allowing for better patient management and infection control.

Cost Implications

Reduce costly operator errors and re-tests with system process checks to ensure accuracy. Fully automated testing means staff can focus on other activities during processing. Our ready-to-use, unit-dose format with 60-day onboard stability helps to reduce waste.


* The Panther Fusion SARS-CoV-2 assay has not been FDA cleared or approved: This test has been authorized by FDA under an EUA for use by authorized laboratories; The Panther Fusion SARS-CoV-2 assay has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The Panther Fusion SARS-CoV-2 assay is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
† Not available in the US
References: 1. Panther Fusion MRSA assay. OUS package insert AW-18028. Hologic, Inc.; 2018. 2. Hologic, Inc. Data on File. 2018.
Want Image Slider on Tab Click
no